IL1B and breast cancer: Interestingly, in the 4T1 immunocompetent model of breast cancer, changes in intra-tumoral IL-1β levels correlate negatively with changes in MDSC infiltration after three weeks of therapy (Fig. 6D, Table 2), where increases in IL-1β following treatment with mcr84 were associated with reduced MDSC infiltration.